Review
Biochemistry & Molecular Biology
Nicholas Noverati, Rukaiya Bashir-Hamidu, Dina Halegoua-DeMarzio, Hie-Won Hann
Summary: Hepatitis B virus is a significant cause of hepatocellular carcinoma globally. The complex mechanisms of this virus include interactions with the host's immune system. Factors such as stress can amplify these mechanisms. Chronic stress, harmful to health, can suppress or activate the host's defense system, leading to tumor initiation and progression in liver cancer. Chronic stress, often overlooked, should be recognized as a potential risk factor.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Cai-Zhi Huang, Jie Zhang, Lin Zhang, Cui-Hua Yu, Yi Mo, Li-Ya Mo
Summary: Children with CHB have lower serum levels of 25(OH)D and VDBP than healthy controls. VDBP levels are negatively correlated with HBV replication, while low 25(OH)D levels are independently associated with hepatic fibrosis in children with CHB. There is no significant correlation between serum levels of 25(OH)D and VDBP.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Immunology
Jie Li, Hwai- Yang, Ming-Lun Yeh, Michael H. Le, An K. Le, Yee Hui Yeo, Chia-Yen Dai, Scott Barnett, Jian Q. Zhang, Jee-Fu Huang, Huy N. Trinh, Christopher Wong, Clifford Wong, Joseph K. Hoang, Ramsey Cheung, Ming-Lung Yu, Mindie H. Nguyen
Summary: This study found that concurrent FL in patients with CHB significantly reduces the risk of cirrhosis and HCC, as well as increases the rate of HBsAg seroclearance. Further research is needed to confirm these findings and investigate the underlying mechanisms of FL on CHB.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Review
Virology
Giacomo Emanuele Maria Rizzo, Giuseppe Cabibbo, Antonio Craxi
Summary: Hepatitis B virus (HBV) infection is associated with the risk of developing hepatocellular carcinoma (HCC), with or without liver cirrhosis, through various mechanisms. The molecular profile of HBV-HCC is constantly being studied, and it is the result of altered molecular pathways, changes in the microenvironment, and DNA damage. Proper management of HBV-related liver disease is crucial for prevention and treatment of HCC.
Article
Oncology
Meng Xue, Xiaona Lin, Qiu-Xiong Lin, Xiaoyong Pu, Jiumin Liu, Xing-Fang Li, Jun Hou, Xudong Liu, Ren Chen
Summary: This study found that HBV infection was associated with an increased risk of HCC compared to HEV infection, and that HEV infection may mitigate the promoting impact of HBV on HCC development.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Virology
Patrizia Farci, Grazia Anna Niro, Fausto Zamboni, Giacomo Diaz
Summary: Hepatitis D virus (HDV) is a small RNA virus that relies on hepatitis B virus (HBV) for virion assembly and transmission, and can lead to chronic hepatitis D. Studies have shown that HDV is associated with a significantly higher risk of hepatocellular carcinoma (HCC) compared to HBV monoinfection. The mechanisms by which HDV promotes liver cancer are still unclear, but recent data suggest that HDV and HBV promote carcinogenesis through distinct molecular mechanisms.
Review
Microbiology
Maria Bousali, George Papatheodoridis, Dimitrios Paraskevis, Timokratis Karamitros
Summary: HBV is an Old World virus with a high mutation rate, originating in Africa alongside Homo sapiens. It can lead to chronic infection by integrating its genome into host DNA, affecting various genes including those related to cell proliferation and oncogenes.
Article
Oncology
Yuan-Hung Kuo, Tzu-Hsin Huang, Jing-Houng Wang, Yen-Yang Chen, Ming-Chao Tsai, Yen-Hao Chen, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Chao-Hung Hung
Summary: This study confirms that while HCV-HCC patients may have a better prognosis when using sorafenib, there is no difference in prognosis between HBV-HCC and HCV-HCC patients when it comes to controlling viral load. The control of viral load is associated with prognosis, while HBV or HCV infection is not.
Review
Medicine, General & Internal
Mirjam B. Zeisel, Francesca Guerrieri, Massimo Levrero
Summary: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is largely caused by chronic hepatitis B virus (HBV) infection. While antiviral therapies can suppress viral replication, there is currently no cure for chronic HBV infection. HBV contributes to liver carcinogenesis through direct and indirect effects on host epigenetic alterations, modulating gene expression.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, Antje Blank, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatyana Stepanova, Annemarie Berger, Dmitry Manuilov, Vithika Suri, Qi An, Ben Da, John Flaherty, Anu Osinusi, Yang Liu, Uta Merle, Julian Schulze zur Wiesch, Stefan Zeuzem, Sandra Ciesek, Markus Cornberg, Pietro Lampertico
Summary: Bulevirtide treatment reduces HDV RNA and ALT levels in patients with chronic hepatitis D, with a dose-dependent effect.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, Antje Blank, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatyana Stepanova, Annemarie Berger, Dmitry Manuilov, Vithika Suri, Qi An, Ben Da, John Flaherty, Anu Osinusi, Yang Liu, Uta Merle, Julian Schulzezur Wiesch, Stefan Zeuzem, Sandra Ciesek, Markus Cornberg, Pietro Lampertico
Summary: In this study, it was found that bulevirtide is effective in inhibiting the entry of hepatitis D virus and reducing the progression of liver disease in patients with chronic hepatitis B. The recommended dosage of bulevirtide is 2 mg or 10 mg per day.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Virology
Ana Caroline Ferreira da Silva, Marlone Cunha-Silva, Tiago Seva-Pereira, Daniel F. Mazo
Summary: This study evaluated the performance of PAGE-B and mPAGE-B scores for hepaticcellular carcinoma (HCC) prediction in Brazilian patients with hepatitis B virus (HBV). The results showed that older age, male sex, and cirrhosis at HBV diagnosis were independently associated with HCC occurrence. Both PAGE-B and mPAGE-B scores showed a correct prediction of HCC above 70% in this cohort.
Article
Gastroenterology & Hepatology
Hyun-seok Kim, Xian Yu, Jennifer Kramer, Aaron P. Thrift, Pete Richardson, Yao-Chun Hsu, Avegail Flores, Hashem B. El-Serag, Fasiha Kanwal
Summary: This study evaluated the performance of 10 HCC risk prediction models in patients with HBV, showing that most models performed well in predicting HCC risk and identified low-risk subsets for exclusion from HCC surveillance. Further research is needed to validate these findings.
JOURNAL OF HEPATOLOGY
(2022)
Review
Oncology
Xinhe Zhang, Lin Guan, Haoyu Tian, Zilu Zeng, Jiayu Chen, Die Huang, Ji Sun, Jiaqi Guo, Huipeng Cui, Yiling Li
Summary: HCC is a common cancer with increasing incidence caused by HBV and HCV infections, liver cirrhosis, and metabolic risk factors. Predictive factors can assess the risk of HCC, and prevention strategies include vaccination, antiviral treatment, and HCC management to reduce recurrence.
FRONTIERS IN ONCOLOGY
(2021)
Review
Gastroenterology & Hepatology
Coskun Ozer Demirtas, Maurizia Rossana Brunetto
Summary: HCC risk stratification can be achieved through various scoring systems, but their optimal performance is limited to populations with highly homogenous characteristics, posing a major obstacle to their sustainable use in clinical practice.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Yung-Tsung Li, Chun-Jen Liu, Jia-Horng Kao, Li-Feng Lin, Hui-Chu Tu, Chih-Chiang Wang, Po-Hsi Huang, Huei-Ru Cheng, Pei-Jer Chen, Ding-Shinn Chen, Hui-Lin Wu
Summary: MTA1 is a generic RNA-binding protein that regulates gene expression posttranscriptionally by binding to MYC in the cytoplasm, and its interaction with MYC is associated with early recurrence in patients with HBV-HCC.
Article
Gastroenterology & Hepatology
Hannah S. J. Choi, Grishma Hirode, Chien-Hung Chen, Tung-Hung Su, Wai-Kay Seto, Stijn Van Hees, Margarita Papatheodoridi, Sabela Lens, Grace L. H. Wong, Sylvia M. Brakenhoff, Rong-Nan Chien, Jordan J. Feld, Milan J. Sonneveld, Henry L. Y. Chan, Xavier Forns, George Papatheodoridis, Thomas Vanwolleghem, Man-Fung Yuen, Yao-Chun Hsu, Jia-Horn Kao, Markus Cornberg, Bettina E. Hansen, Wen-Jue Jeng, Harry L. A. Janssen
Summary: This study compared the relapse rates and treatment outcomes after discontinuation of therapy in chronic hepatitis B patients using entecavir (ETV) and tenofovir disoproxil fumarate (TDF). It found that TDF was associated with a higher rate of HBsAg loss, earlier virological relapse, and higher clinical relapse compared to ETV. However, the rates of HBsAg loss and retreatment were similar between the two treatment groups. Finite therapy can be considered for CHB patients on either TDF or ETV therapy.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Grishma Hirode, Bettina E. Hansen, Chien-Hung Chen, Tung-Hung Su, Grace Wong, Wai-Kay Seto, Stijn Van Hees, Margarita Papatheodoridi, Sylvia M. Brakenhoff, Sabela Lens, Hannah S. J. Choi, Rong-Nan Chien, Jordan J. Feld, Xavier Forns, Milan J. Sonneveld, George V. Papatheodoridis, Thomas Vanwolleghem, Man-Fung Yuen, Henry L. Y. Chan, Jia-Horng Kao, Yao-Chun Hsu, Markus Cornberg, Wen-Juei Jeng, Harry L. A. Janssen
Summary: Despite improvements in the management of chronic hepatitis B, the risk of cirrhosis and hepatocellular carcinoma remains. The rate of hepatic decompensation is low after discontinuation of nucleos(t)ide analog therapy, but higher in patients with cirrhosis and those who were HBeAg positive at the start of therapy.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Oncology
Chian-Tzu Huang, Yu-Long Chu, Tung-Hung Su, Shang-Chin Huang, Tai-Chung Tseng, Shih-Jer Hsu, Sih-Han Liao, Chun-Ming Hong, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
Summary: This study aimed to identify candidates for surgical resection (SR) in Barcelona Clinic Liver Cancer (BCLC) -A/B HCC beyond the Milan criteria with survival benefit. The study found that patients with tumor burden beyond the up-to-7 criteria but within 3 tumors had better overall survival (OS) with SR compared to transarterial chemoembolization (TACE), suggesting that SR should be considered in resectable patients.
Editorial Material
Medicine, General & Internal
Jia-Horng Kao
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2023)
Editorial Material
Medicine, General & Internal
Jia-Horng Kao
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2023)
Article
Medicine, General & Internal
Tung-Hung Su, Shang-Chin Huang, Chi-Ling Chen, Shih-Jer Hsu, Sih-Han Liao, Chun-Ming Hong, Tai-Chung Tseng, Chen-Hua Liu, Hung-Chih Yang, Yao-Ming Wu, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
Summary: This study found that preoperative GGT levels ≥ 38 U/L in patients with HBV-related HCC independently predict high risks of HCC recurrence and all-cause mortality. This finding can aid in the clinical diagnosis and management of HCC patients.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2023)
Article
Medicine, General & Internal
Ming-Lung Yu, Chih-Yuan Wang, Mei-Hsuan Lee, Horng-Yih Ou, Pin-Nan Cheng, Shih-Te Tu, Jee-Fu Huang, Jung-Fu Chen, Tsung-Hui Hu, Chih-Cheng Hsu, Jia-Horng Kao, Chien-Jen Chen, Han-Chieh Lin, Chien-Ning Huang
Summary: Diabetes mellitus and hepatitis C virus infection are prevalent globally, and there is a bidirectional association between the two. Direct-acting antivirals for HCV have high treatment success rates and can reduce short-term and long-term complications. However, previous guidelines did not focus on universal HCV screening for diabetic patients. Screening for HCV among patients with diabetes can contribute to the eradication of HCV infection.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2023)
Article
Medicine, General & Internal
Chen-Hua Liu, Yu-Jen Fang, Chun-Jen Liu, Tung-Hung Su, Shang-Chin Huang, Tai-Chung Tseng, Jo-Hsuan Wu, Pei-Jer Chen, Jia-Horng Kao
Summary: Retrospective study showed that the splenic arterial pulsatility index (SAPI) was closely associated with the severity of hepatic fibrosis in hemodialysis patients with chronic HCV infection. The diagnostic accuracy of SAPI was comparable to the fibrosis index based on four parameters (FIB-4) and superior to the aspartate transaminase (AST)-to-platelet ratio index (APRI). The positive predictive value (PPV) for >= F1 was 79.5%, and the negative predictive values (NPVs) for >= F2, >= F3, and F4 were 79.8%, 92.6%, and 96.9%, respectively, when the maximal Youden indices were used.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Yu-Ming Cheng, Tsung-Han Hsieh, Chia-Chi Wang, Jia-Horng Kao
Summary: The new name and diagnostic criteria of metabolic-associated fatty liver disease (MAFLD) were proposed in 2020. The impact of chronic HBV infection on clinical outcomes of MAFLD was investigated using a Taiwan bio-bank cohort. The study revealed that chronic HBV infection increases the overall risk of liver fibrosis, but protects from atherosclerosis in patients with MAFLD.
Article
Gastroenterology & Hepatology
Young-Suk Lim, Henry L. Y. Chan, Sang Hoon Ahn, Wai Kay Seto, Qin Ning, Kosh Agarwal, Harry L. A. Janssen, Calvin Q. Pan, Wan Long Chuang, Namiki Izumi, Scott Fung, Maurizia Shalimar, Maurizia Brunetto, Aric Josun Hui, Ting-Tsung Chang, Seng Gee Lim, Frida Abramov, John F. Flaherty, Hongyuan Wang, Leland J. Yee, Jia-Horng Kao, Edward Gane, Jinlin Hou, Maria Buti
Summary: This study evaluated the impact of tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) on the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). The study found that patients receiving TAF treatment had a lower risk of HCC compared to those receiving TDF treatment, especially in patients without cirrhosis.
Correction
Gastroenterology & Hepatology
Yu-Ming Cheng, Tsung-Han Hsieh, Chia-Chi Wang, Jia-Horng Kao
Meeting Abstract
Gastroenterology & Hepatology
Grishma Hirode, Bettina Hansen, Chien-Hung Chen, Tung-Hung Su, Grace Wong, Wai-Kay Seto, Arno Furquim d'Almeida, Margarita Papatheodoridi, Sylvia Brakenhoff, Sabela Lens, Hannah S. J. Choi, Stijn Van Hees, Rong-Nan Chien, Jordan J. Feld, Xavier Forns, Milan Sonneveld, George Papatheodoridis, Thomas Vanwolleghem, Man-Fung Yuen, Henry L. Y. Chan, Jia-Horng Kao, Yao-Chun (Holden) Hsu, Markus Cornberg, Rachel Wen-Juei Jeng, Harry L. A. Janssen
JOURNAL OF HEPATOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Chung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, Ching-Chu Lo, Chao-Hung Hung, Chien-Wei Huang, Lee-Won Chong, Pin-Nan Cheng, Ming-Lun Yeh, Cheng-Yuan Peng, Chien-Yu Cheng, Jee-Fu Huang, Ming-Jong Bair, Chih-Lang Lin, Chi-Chieh Yang, Sih-Ren Wang, Tsai-Yuan Hsieh, Tzong-Hsi Lee, Pei-Lun Lee, Wen-Chih Wu, Chih-Lin Lin, Wei-Wen Su, Shengshun Yang, Chia-Chi Wang, Jui-Ting Hu, Lien-Juei Mou, Chun-Ting Chen, Yi-Hsiang Huang, Chun-Chao Chang, Jia-Sheng Huang, Guei-Ying Chen, Jian-Neng Gao, Chi-Ming Tai, Chun-Jen Liu, Mei-Hsuan Lee, Pei-Chien Tsai, Chia-Yen Dai, Jia-Horng Kao, Han-Chieh Lin, Wan-Long Chuang, Chiyi Chen, Kuo-Chih Tseng, Ming-Lung Yu
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Chen-Hua Liu, Chun-Jen Liu, Tung-Hung Su, Tai-Chung Tseng, Pei-Jer Chen, Jia-Horng Kao
Summary: This study analyzed the patient characteristics and clinical performance of retreatment with pangenotypic direct-acting antivirals (DAAs) in patients with hepatitis C virus (HCV) reinfection after viral clearance. The risk of reinfection was higher in HIV-positive patients than HIV-negative patients. Treating reinfected patients with pangenotypic DAAs showed excellent effectiveness and tolerance, regardless of prior DAA exposure or viral genotypes/subtypes.
ADVANCES IN DIGESTIVE MEDICINE
(2023)
